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BTLA (C272) expression on CD4+ T cells in Behçet patients*
Nafiye Fulya İLHAN1, Nesrin DEMİR1, Tamer DEMİR2, Ahmet GÖDEKMERDAN1

Aim: To investigate the peripheral blood levels of B and T lymphocyte attenuator (BTLA/CD272) on T cells and its role
in Behçet disease (BD), and to define the role of inhibitory receptors on BD.
Materials and methods: Included in this study were 25 patients with BD and 20 healthy control subjects, matched for
age and sex.
Results: CD4+CD272+ (P < 0.001) and CD3+CD272+ (P < 0.001) T cell levels were significantly higher in BD patients
(active and remission) compared to the healthy controls. However, there was no difference between the active patients
and those in remission in terms of CD4+CD272+ T cells, while CD3+CD272+ T cell levels were significantly higher in
active-phase BD patients compared to patients in the remission phase (P < 0.05).
Conclusion: Further functional studies could be implemented to investigate the effectiveness of the present research
parameter in the diagnosis or follow-up of certain diseases similar to BD and with obscure etiology, as well as its
contribution to immune dysregulation of BD. BTLA can additionally modulate T cell response in BD on different
inflammatory areas and it can be upregulated in BD because of T cell activation. The results of the present study indicate
that BTLA expression on CD4+ Th (T helper) cells might play a limiting role on the inflammation at peripheral sites or
organs in BD.
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Introduction
The immune system is a dynamic process regulated
by the balance between different inhibition and
activation signals. Knowledge of the inhibitor
receptor family is gradually extending at present
(1). The recently discovered B and T lymphocyte
attenuator (BTLA/CD272) is an inhibitor receptor
expressed on T cells, and it negatively regulates the
cell activation through phosphatases SHP-1/SHP-2.
It has similar structure and function with cytotoxic
T-lymphocyte antigen-4 (CTLA-4) and programmed
death 1 (PD-1) (2). Herpes virus entry mediator
(HVEM) is a receptor interacting with BTLA and

is defined as a member of the superfamily of tumor
necrosis factor receptors (3). HVEM is generally
expressed on resting T cells, monocytes, immature
dendritic cells (DCs), and endothelial cells (4,5). On
the other hand, BTLA is expressed on naive CD4+
and CD8+ T cells and then upregulated with T cell
activation (6). BTLA is also present in the B cells,
macrophages, and DCs of bone marrow origin. T cell
receptor (TCR) and HVEM stimulation regulates the
surface expression of BTLA and the accumulation in
immunologic synapses, and it enables the creation of
inhibitor signals, which are effective in the regulation
of CD4+ T cell activation (7,8).
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Because BTLA is a negative receptor, T cells give
high response rates to TCR-related activation in mice
deficient in the full-length form of BTLA (2). Mice
deficient in BTLA or its ligand HVEM were reported
to be more susceptible to immune and inflammatory
diseases and showed severe pathological tissue
changes like experimental allergic encephalomyelitis,
allergic airway inflammation, and intestinal
inflammation. Behçet disease (BD) is a chronic
inflammatory disease and is strictly related to T cell
stimulation and inflammation. Consequently, the
BTLA pathway is considered to have a critical role
in immune-inflammatory diseases such as BD (9,10).

cytometry technique was used to analyze CD4 FITC
(IM0448), CD3 PerCP (IM 0479), and CD272 PE
(eBioscience 12-5950). Analytic flow cytometry
was carried out by counting a total of 10,000 cells,
using the Coulter EPICS XL-MCL device (Beckman
Coulter, USA). Analyses were made using the Expo32 analysis program with the same equipment.
Statistical analyses were carried out with SPSS 11.0
for Windows (SPSS Inc., USA). The Mann-Whitney
U and Kruskal-Wallis tests were used, and P < 0.05
was considered statistically significant.
Results

Materials and methods
This study was approved by the local ethics committee
of Fırat University, Elazığ, Turkey. Patients were
diagnosed with BD according to the diagnostic
criteria of the International Study Group for BD.
Twenty-five BD patients and 20 age-matched healthy
control subjects were included in the study. Of the
BD patients, 13 were at the active stage of BD and
the remaining 12 were in an inactive period. In total,
18 BD patients had ocular complications (9 with
active ocular attacks, 2 with inflammatory arthritis,
and 7 with uveitis in a remission period) and 5 had
mucocutaneous lesions (2 in the active period and 3
in remission).
Blood was collected in EDTA tubes from
peripheral venous blood and all of the samples were
run within 2 h on the same day. The 3-color-flow-

The number of research groups, age distribution of
the control group and BD patients, duration of disease
activation criteria, and therapeutic drugs used by the
BD patients are given in Tables 1-3, respectively.
BD patients (active and remission period) were
observed to have significantly higher CD4+CD272+
percentages (BD patients: 13.01 ± 1.51%, healthy
controls: 2.90 ± 0.814%; P < 0.001) and CD3+CD272+
T cell percentages (BD patients: 23.79 ± 2.27%,
healthy controls: 6.27 ± 1.27%; P < 0.001) compared
to the healthy controls. There was no difference in
the CD4+CD272+ T cell percentages in BD patients in
the active and remission phases (active phase: 11.43
± 2.41%, remission phase: 14.11 ± 1.95%; P > 0.05).
However, the CD3+CD272+ values were significantly
different in BD patients in the active and remission
phases (active phase: 1.06 ± 3.48%, remission phase
27.06 ± 2.74%; P < 0.05) (Figures 1-3).

Table 1. The age distribution of the control and BD groups and the duration of disease.

Control
x– ± Sx–

BD
x– ± Sx–
Age (years)

37.45

3.25

Active
x– ± Sx–

Remission
x– ± Sx–

4.39 ± 1.29

8.13 ± 2.04

Disease duration (years)

774

29.56

2.97
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Table 2. Activation criteria in patients with active BD.

Patients with active BD

Table 3. Therapeutic drugs used by BD patients.

Therapeutic drugs

Inactive
(n: 13)

Active
(n: 12)

Activation criteria

n

(%)

Sumatriptan use (%)

30.76

33.33

Uveitis

9

69.23

Sulfasalazine use (%)

30.76

16.66

Oral/genital ulcers

2

15.38

Colchicum-Dispert use (%)

61.53

75.00

Prednisolone use (%)

15.38

25.00
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Figure 1. The distribution of BTLA levels in the BD patient and
control groups.

Discussion
Previous studies demonstrated that inhibitor
coreceptors like BTLA are related to the
maintenance of homeostasis and tolerance, and, in
addition, they inhibit lymphocyte activation (11).
In a study reporting that BTLA had an essential
role in the maintenance of self-tolerance and thus
protected the host from autoimmunity, increases
were detected in autoantibodies to nuclear antigens,
hypergammaglobulinemia, and the peripheral
active T cells of BTLA−/− mice at 12 months of age.
In addition, self-activated CD4+ T and natural
killer T cells were also increased in BTLA−/−
mice. Researchers observed a disease similar to
autoimmune hepatitis and inflammatory changes

Figure 2. CD272 expression on CD3+ T cells in BD patients.

similar to Sjögren syndrome in the salivary glands,
lungs, and pancreas. Development of these diseases
was attributed to the breakdown in the maintenance
of self-tolerance. On the other hand, the same
researchers also observed that the susceptibility
to experimental autoimmune encephalomyelitis
was increased in BTLA−/− mice (2). Accordingly,
BTLA was found to be related to the maintenance
of tolerance to self-antigens and it played a negative
regulatory role in the development of autoimmune
diseases (11). Different studies demonstrated the
importance of T cells in the pathophysiology of
airway inflammation and reported that airway
inflammation lasted longer in BTLA-deficient mice
(12).
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are required to determine the roles of inhibitor
pathway defects as biological reasons for certain
inflammatory diseases (14).

103

Of the inhibitory molecules, CTLA-4 controls the
naive T cell activation, while PD-1 is responsible for
T cell activation. On the other hand, BTLA is found
both on naive and activated T cells and it can control
the whole phases of T cell activation, though it is
more prevalent on tolerant T cells (15).
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Figure 3. CD272 expression CD4+ T cells in BD patients.

Previous studies have indicated that BTLA and
PD-1 inhibitor receptors are indispensable parts of
acute allergic respiratory tract inflammation (9). In
vitro studies demonstrated that BTLA inhibits T cell
proliferation (3). Autoimmune encephalomyelitis
disorder was even more severe in BTLA-deficient
mice. Therefore, BTLA was considered to have
dominant inhibitory roles (2).
The inhibitory signals formed by CTLA-4
are highly important in the early phases of T cell
response, while inhibitory signals through PD-1 and
BTLA pathways, in addition to other receptors, gain
importance in the later immune response. Therefore,
inhibitor signals through PD-1 and BTLA pathways
reduce the inflammatory response rate by dominating
over activated signals (13). Immune regulation gains
even more importance in this regard. Further studies

BTLA is known to have strong effects on
T cell activation in BD that develops uncontrolled
inflammatory response on account of a dysfunction
in T cell activation; therefore, the expression of BTLA
on total T and CD4+ T cells was investigated in the
present study. The aim was to gain knowledge about
the expression of inhibitory receptors in BD based on
the BTLA inhibitory receptor. BTLA expression was
observed to increase in T cells in the peripheral cycle
of BD patients compared to the healthy controls.
BTLA binding creates an inhibitory signal to T cells,
and thus could play an important role in terms of T
cell tolerance. In addition, BTLA could regulate T
cell responses in different inflammatory areas in BD.
BTLA expression on CD4+ Th cells could have a role
in the control of inflammation in peripheral sites or
organs. Autoimmune events and graft denial increase
in BTLA deficiency, which indicates its possible role in
autoinflammatory pathogenesis in BD. High levels of
BTLA on T cells could limit increased inflammation
and autoimmune events. These results indicate that
BTLA plays a critical role in the maintenance of selftolerance and prevention of autoimmune diseases;
in addition, increasing BTLA through the signals of
agonistic ligands could be helpful in the treatment
of autoimmune diseases. Additional detailed and
functional studies are necessary for further evaluation
of the role of BTLA on BD.
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